Evidence map›Paper›PMID 36426217›Full record

ArticleFrontiers in cardiovascular medicine2022

Radiation therapy induces immunosenescence mediated by p90RSK.

Masaki Imanishi, Haizi Cheng, Sivareddy Kotla, Anita Deswal, Nhat-Tu Le, Eduardo Chini, Kyung Ae Ko, Venkata S K Samanthapudi, Ling-Ling Lee, Joerg Herrmann and 15 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Continuous βClinical and translational radiation oncology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Metabolic regulation of endothelial senescence.Frontiers in cardiovascular medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Masaki ImanishiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Haizi ChengCenter for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Sivareddy KotlaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Anita DeswalDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nhat-Tu LeDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Eduardo ChiniDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, FL, United States.
Kyung Ae KoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Venkata S K SamanthapudiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ling-Ling LeeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Joerg HerrmannDivision of Preventive Cardiology, Cardio Oncology Clinic, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Xiaolei XuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States.
Cielito Reyes-GibbyDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sai-Ching J YeungDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keri L SchadlerDepartment of Pediatric Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Syed Wamique YusufDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Zhongxing LiaoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Roza NurievaDivision of Basic Science, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
El-Ad David AmirAstrolabe Diagnostics, Inc., Fort Lee, NJ, United States.
Jared K BurksDivision of Center Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nicolas L PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
John P CookeDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States.
Steven H LinDepartment of Pediatric Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Michihiro KobayashiCenter for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Momoko YoshimotoCenter for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
Jun-Ichi AbeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USHouston Methodist · USMayo Clinic in Arizona · USWinnMed · US

Funding

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patientsR01HL157273 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIAO, ZHONGXING · 2021 to 2025
$3.8M
Therapeutic implication of CD38 in CLLR01CA233790 · NCI · MAYO CLINIC JACKSONVILLE · PI CHINI, EDUARDO N · 2019 to 2023
$3.0M
Premature aging disorders, metabolites, and atherosclerosisR01HL163857 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jun-Ichi Abe, JOHN P COOKE · 2023 to 2026
$2.9M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Mitigating radiation-induced cardiovascular disease by inhibiting premature agingU01AI156921 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABE, JUN-ICHI · 2020 to 2024
$2.5M
Role of CD38 in NAD metabolism: from the basic biology of aging to translationR01AG058812 · NIA · MAYO CLINIC ROCHESTER · PI CHINI, EDUARDO N · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA233610NCI NIH HHS R01 CA233790NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL157273NHLBI NIH HHS R01 HL163857NIAID NIH HHS U01 AI156921NIA NIH HHS R01 AG058812
6 · The paper itself

Abstract

Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both cancer risk and CVD development. Therefore, suppression of immunosenescence can be an ideal target to prevent cancer treatment-induced CVD. However, the mechanism(s) by which cancer treatments induce immunosenescence are incompletely characterized. We isolated peripheral blood mononuclear cells (PBMCs) before and 3 months after RT from 16 thoracic cancer patients. We characterized human immune cell lineages and markers of senescence, DNA damage response (DDR), efferocytosis, and determinants of clonal hematopoiesis of indeterminant potential (CHIP), using mass cytometry (CyTOF). We found that the frequency of the B cell subtype was decreased after RT. Unsupervised clustering of the CyTOF data identified 138 functional subsets of PBMCs. Compared with baseline, RT increased TBX21 (T-bet) expression in the largest B cell subset of Ki67

Indexed as

CD38immunosenescencep90RSKradiotherapyT-bet

Identifiers

PMID36426217
PMCPMC9680092
OpenAlexW4308584580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.